{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T15:41:29Z","timestamp":1769269289091,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00259-025-07447-0","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T06:53:06Z","timestamp":1753080786000},"page":"824-832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["[177Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastases"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8258-1774","authenticated-orcid":false,"given":"Gokce","family":"Belge Bilgin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Burkett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew P.","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann T.","family":"Packard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Fidanli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Muniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob J.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Fernando","family":"Quevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sani H.","family":"Kizilbash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene D.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse Tuba","family":"Kendi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"7447_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: Cancer J Clin. 2023;73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA: Cancer J Clin"},{"key":"7447_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1158\/1055-9965.Epi-22-1038","volume":"32","author":"TP Devasia","year":"2023","unstructured":"Devasia TP, Mariotto AB, Nyame YA, Etzioni R. Estimating the number of men living with metastatic prostate cancer in the United States. Cancer Epidemiol Biomark Prev. 2023;32:659\u201365. https:\/\/doi.org\/10.1158\/1055-9965.Epi-22-1038.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"7447_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.clgc.2020.07.012","volume":"19","author":"PJ Boxley","year":"2021","unstructured":"Boxley PJ, Smith DE, Gao D, Kessler ER, Echalier B, Bernard B, et al. Prostate cancer central nervous system metastasis in a contemporary cohort. Clin Genitourin Cancer. 2021;19:217-22.e1. https:\/\/doi.org\/10.1016\/j.clgc.2020.07.012.","journal-title":"Clin Genitourin Cancer"},{"key":"7447_CR4","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1016\/j.wneu.2020.02.152","volume":"138","author":"HP Bhambhvani","year":"2020","unstructured":"Bhambhvani HP, Greenberg DR, Srinivas S, Gephart MH. Prostate cancer brain metastases: a single-institution experience. World neurosurgery. 2020;138:e445\u20139.","journal-title":"World neurosurgery"},{"key":"7447_CR5","doi-asserted-by":"publisher","unstructured":"Rajeswaran K, Muzio K, Briones J, Lim-Fat MJ, Tseng CL, Smoragiewicz M, et al. Prostate cancer brain metastasis: review of a rare complication with limited treatment options and poor prognosis. J Clin Med. 2022;11. https:\/\/doi.org\/10.3390\/jcm11144165.","DOI":"10.3390\/jcm11144165"},{"key":"7447_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, Bono JSD, Molina A, Logothetis CJ, Souza PD, et al. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med. 2013;368:138\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1209096.","journal-title":"N Engl J Med."},{"key":"7447_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1405095.","journal-title":"N Engl J Med"},{"key":"7447_CR8","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"JD Bono","year":"2020","unstructured":"Bono JD, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102. https:\/\/doi.org\/10.1056\/NEJMoa1911440.","journal-title":"N Engl J Med."},{"key":"7447_CR9","doi-asserted-by":"publisher","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1:EVIDoa2200043. https:\/\/doi.org\/10.1056\/EVIDoa2200043.","journal-title":"NEJM Evid."},{"key":"7447_CR10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804. https:\/\/doi.org\/10.1016\/s0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"7447_CR11","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.2967\/jnumed.121.261982","volume":"62","author":"J Calais","year":"2021","unstructured":"Calais J, Gafita A, Eiber M, Armstrong WR, Gartmann J, Thin P, et al. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant prostate cancer (RESIST-PC): efficacy results of the UCLA cohort. J Nucl Med. 2021;62:1440\u20136. https:\/\/doi.org\/10.2967\/jnumed.121.261982.","journal-title":"J Nucl Med"},{"key":"7447_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, Bono JD, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med."},{"key":"7447_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83:405\u201312. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002.","journal-title":"Eur Urol"},{"key":"7447_CR14","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.2967\/jnumed.124.267643","volume":"65","author":"G Belge Bilgin","year":"2024","unstructured":"Belge Bilgin G, Burkett BJ, Bilgin C, Orme JJ, Childs DS, Rincon MM, et al. Neurologic symptoms after (177)Lu-prostate-specific-membrane antigen-617 therapy: a single-center experience. J Nucl Med. 2024;65:1402\u20138. https:\/\/doi.org\/10.2967\/jnumed.124.267643.","journal-title":"J Nucl Med"},{"key":"7447_CR15","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.clgc.2022.10.007","volume":"21","author":"A Jang","year":"2023","unstructured":"Jang A, Jaeger EB, Ledet EM, Xie J, Lewis BE, Layton JL, et al. Clinical and genetic analysis of metastatic prostate cancer to the central nervous system: a single-institution retrospective experience. Clin Genitourin Cancer. 2023;21:e9\u201318. https:\/\/doi.org\/10.1016\/j.clgc.2022.10.007.","journal-title":"Clin Genitourin Cancer"},{"key":"7447_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11060-009-0057-4","volume":"96","author":"TC Ryken","year":"2010","unstructured":"Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:103\u201314. https:\/\/doi.org\/10.1007\/s11060-009-0057-4.","journal-title":"J Neurooncol"},{"key":"7447_CR17","first-page":"241955","volume":"65","author":"R Karri","year":"2024","unstructured":"Karri R, Buteau J, Eifer M, Bollampally N, Bressel M, Sandhu S, et al. Prognostic value of post-therapy SPECT\/CT imaging in patients undergoing [177Lu]Lu-PSMA-617 radioligand therapy: results from 3 clinical trials. J Nucl Med. 2024;65:241955.","journal-title":"J Nucl Med."},{"key":"7447_CR18","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2967\/jnumed.124.267955","volume":"65","author":"S Yadav","year":"2024","unstructured":"Yadav S, Lowery B, Tuchayi AM, Jiang F, Saelee R, Aggarwal RR, et al. Impact of posttreatment SPECT\/CT on patient management during (177)Lu-PSMA-617 radiopharmaceutical therapy. J Nucl Med. 2024;65:1395\u2013401. https:\/\/doi.org\/10.2967\/jnumed.124.267955.","journal-title":"J Nucl Med"},{"key":"7447_CR19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2967\/jnumed.122.264677","volume":"64","author":"N John","year":"2023","unstructured":"John N, Pathmanandavel S, Crumbaker M, Counter W, Ho B, Yam AO, et al. 177Lu-PSMA SPECT quantitation at 6 weeks (Dose 2) predicts short progression-free survival for patients undergoing 177Lu-PSMA-I&T therapy. J Nucl Med. 2023;64:410\u20135. https:\/\/doi.org\/10.2967\/jnumed.122.264677.","journal-title":"J Nucl Med"},{"key":"7447_CR20","doi-asserted-by":"publisher","first-page":"175883592311563","DOI":"10.1177\/17588359231156392","volume":"15","author":"L Emmett","year":"2023","unstructured":"Emmett L, John N, Pathmanandavel S, Counter W, Ayers M, Sharma S, et al. Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). Ther Adv Med Oncol. 2023;15:17588359231156392. https:\/\/doi.org\/10.1177\/17588359231156392.","journal-title":"Ther Adv Med Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07447-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07447-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07447-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:46:33Z","timestamp":1769222793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07447-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7447"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07447-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"27 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Mayo Clinic Institutional Review Board (No. 22\u2013010856).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"B.B. receives research support from GE Healthcare and the Radiological Society of North America. J.J.O. receives research support from the Prostate Cancer Foundation (YIA), Department of Defense, and National Cancer Institute (K12 CA90628-23). J.J.O. previously received research support from Nanotics, Genentech, and Partner Therapeutics. D.C.receives honoraria from Targeted Oncology, IntrinsiQ, MJH Life Sciences, and International Centers for Precision Oncology Foundation Consulting; has an advisory role with Janssen Biotech and Novartis Research Funding: Janssen Biotech; and receives travel and accommodations expenses from the Prostate Cancer Foundation. D.R.J. has a consulting or advisory role with Telix. G.J. has a leadership role with Green Clinic and Nucleus RadioPharma; has a consulting or advisory role with AstraZeneca, Blue Earth Diagnostics, Curium Pharma, MedTrace, MorphImmune, Novartis, Siemens Healthineers, Viewpoint Molecular Targeting, Viewpoint Molecular Targeting, and Z-Alpha; receives research funding from Clarity Pharmaceuticals, Clovis Oncology, MedTrace, Novartis, Pfizer, Viewpoint Molecular Targeting, and Viewpoint Molecular Targeting; and has patents on radiopharmaceuticals. O.S. has stock and other ownership interests in Abbvie, Cardinal Health, Clarity Pharmaceuticals, Convergent Therapeutics, Fusion Pharmaceuticals, Lilly, Ratiopharm, Telix Pharmaceuticals, and United Health Group; receives honoraria from Lantheus Medical Imaging Consulting; has an advisory role with Advanced Accelerator Applications, Amgen, ARTbio, Astellas Pharma, AstraZeneca, Bayer, Blue Earth Diagnostics, Clarity Pharmaceuticals, Fusion Pharmaceuticals, Hengrui Therapeutics, Isotopen Technologien, Janssen, MacroGenics, Medscape, Merck, Northstar, Novartis, Noxopharm, Pfizer, Point Biopharma, Progenics, Ratio, Sanofi, Telix Pharmaceuticals, Tempus, TeneoBio, and Tessa Therapeutics; receives research funding from Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Endocyte, InVitae, Janssen, Lantheus Medical Imaging, Merck, point Biopharma, Progenics, and Sanofi; has patents, royalties, or other intellectual property (Koochekpour S, Sartor AO, inventors. Saposin C and receptors as targets for treatment of benign and malignant disorders. U.S. patent awarded January 23, 2007 [patent 7,166,691]); provides expert testimony for Sanofi; and receives travel and accommodations expenses from AstraZeneca, Bayer, Johnson & Johnson, Lantheus Medical Imaging, Progenics, and Sanofi. A.T.K.has a consulting or advisory role with Novartis Research Funding.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}